tiprankstipranks
Trending News
More News >
Liminatus Pharma, Inc. (LIMN)
:LIMN
US Market
Advertisement

Liminatus Pharma (LIMN) Ownership - Who Owns Liminatus Pharma?

Compare
38 Followers

Liminatus Pharma (LIMN) Ownership Overview

0.27%99.73%
0.27% ETFs
99.73% Public Companies and
Individual Investors
The ownership structure of Liminatus Pharma (LIMN) stock is a mix of institutional, retail, and individual investors. , and 99.73% is owned by Public Companies and Individual Investors.
The ownership structure of Liminatus Pharma (LIMN) stock is a mix of institutional, retail, and individual investors. , 0.27% is owned by Insiders

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
100,000Institution0.38%948,000
73,424Institution0.27%435,404

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
73,424Institution0.27%818,678

FAQ

Who Owns Liminatus Pharma, Inc. (LIMN)?
Currently, no data Available
What percentage of Liminatus Pharma, Inc. (LIMN) stock is held by institutional investors?
Currently, no data Available
What percentage of Liminatus Pharma, Inc. (LIMN) stock is held by retail investors?
According to the latest TipRanks data, approximately 99.73% of Liminatus Pharma, Inc. (LIMN) stock is held by retail investors.
    Who owns the most shares of Liminatus Pharma, Inc. (LIMN)?
    Louis Moore Bacon owns the most shares of Liminatus Pharma, Inc. (LIMN).
      What is the significance of the ownership structure for a publicly traded company?
      The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis